Business » Industry

Updated: January 12, 2014 03:12 IST

Dr. Reddy’s to market Optidoz, an anti-hypertension drug

Special Correspondent
Comment (2)   ·   print   ·   T  T  
The Hindu Optidoz

Dr. Reddy’s Laboratories has announced that its drug Optidoz, for the treatment of hypertension, has been approved and is available for the Indian market. The drug will contribute to over Rs.100 crore revenue in 5-10 years, according to Alok Sonig, Senior Vice-President, India Businesss, Generics, Dr. Reddy’s.

Mr. Sonig, after launching the drug in Hyderabad, said, “the unique drug will address the needs of over 70 million people and will be a significant game changer in the domain of hypertension”.

It also saves Rs.10 per tablet to patients, according to him.


Optidoz is a single pill combination of three drugs — Amlodipine, Telmisartan and Hydrochrothiazide — with optimal dose of individual drugs. A pack of 10 tablets is priced at Rs.80.

The company claims that the drug controls hypertension faster with lesser side effects compared to double dose combinations.

More In: Industry | Business

The drug should get USFD approval soon for universal acceptance.It will be great boon to the mankind.Well done Dr.Reddys Garu

from:  M.Jambunathan
Posted on: Jan 13, 2014 at 00:24 IST

its really a tremendous achievement done by any other Indian Pharmaceutical company in hypertension management

from:  rasmiranjan
Posted on: Jan 12, 2014 at 19:56 IST
This article is closed for comments.
Please Email the Editor
Both the tech giants have now decided to drop the patent cases in all other countries except U.S. Photo: AP

Timeline: Apple and Samsung patent game-play

2007: Apple sued its component supplier Samsung for four design patents, which included the basic shape of iPhone. It declared that most of the South Korean Company's android phon... »
Should India restrict foreign investors in a globalised world?
Can't say






Recent Article in Industry

SBI to revise interest rates on retail term deposits below Rs.1 crore

Effective from September 18, the new interest rate will be 8.75 per cent. »